MRVL Marvel Biosciences Corp.
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Marvel Biosciences (CVE: MRVL)
›
Marvel Biosciences (CVE: MRVL) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.1150 CAD on 19 November 2026, down 36.1% over 52 weeks. Its 52-week range is 0.0950 CAD to 0.2500 CAD: the price is 54.0% below the high and 21.1% above the low.
Its market capitalisation is 8.47M CAD.
Marvel Biosciences reports return on equity of 55.2% and an operating margin of 0.0%.
Its debt exceeds its cash by 961.20K CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.